Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

ISAP trial team outside the Oxford Health building

We reached a milestone today with the first participant randomisation visit for the ISAP trial. ISAP investigates the effect of oral semaglutide compared with placebo on the brain in individuals at risk for Alzheimer’s disease.

Thank you to the study participants, Oxford Health NIHR Clinical Research FacilityDementias Platform UK, Oxford Health Biomedical Research Centre, and the funder Novo Nordisk who supported this investigator initiated study.

[More information about the ISAP trial]